Setterwalls has advised RhoVac in connection with a rights issue of approximately SEK 180.9 million

Setterwalls has advised RhoVac AB in connection with a rights issue of shares. Through the rights issue, RhoVac AB will receive gross proceeds of approximately SEK 180.9 million.

RhoVac AB is a biotechnology company conducting research and development of immunotherapeutic drugs. The company’s main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer.